Erika Gonzalez, MD
Allergy & Immunology · San Antonio, TXNPI 1427022516
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $33,470 of the $51,610 with a category attached, or 64.9%. 36 manufacturers reported payments, led by GSK at 34.8% of the total. Reporting peaked in 2021 at $11,047 and has fallen 80.2% since, to $2,183 in 2025. Among allergy & immunology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 472 payments — averaging $109.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$18K
- Astrazeneca UK Limited$7K
- Regeneron$7K
- Sanofi$5K
- Novartis$4K
- Genentech USA, Inc.$2K
- plus $9K from 30 others
Across 1,060 payments — averaging $2012.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$546K
- Novartis$440K
- Teva Pharmaceuticals USA, Inc.$244K
- Astrazeneca UK Limited$162K
- Sanofi US Services Inc.$158K
- Regeneron$148K
- plus $436K from 8 others
What the payments were for
- Consulting fees$33,47065%
- Speaking & faculty fees$2,6805%
- Travel & lodging$4,8649%
- Food & beverage$10,45520%
- Education$1410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 78 | $17,968 |
| Astrazeneca UK Limited | 8 | $6,920 |
| Regeneron | 5 | $6,514 |
| Sanofi | 47 | $4,695 |
| Novartis | 40 | $4,009 |
| Genentech USA, Inc. | 37 | $2,412 |
| Teva Pharmaceuticals USA, Inc. | 5 | $1,737 |
| Regeneron Healthcare Solutions, Inc. | 46 | $1,416 |
| AstraZeneca | 48 | $1,343 |
| Sanofi-aventis U.S. LLC | 45 | $955 |
| Optinose US, Inc. | 6 | $861 |
| Medtronic | 1 | $411 |
| Amgen(2 entities) | 15 | $299 |
| ARS Pharmaceuticals Operations, Inc. | 10 | $252 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $199 |
| CSL Behring | 12 | $180 |
| Genentech, Inc. | 2 | $173 |
| Octapharma USA, Inc. | 5 | $169 |
| Galderma Laboratories, L.p. | 3 | $122 |
| Pfizer | 7 | $102 |
| Alk-abello, Inc | 6 | $98 |
| Kaleo, Inc. | 5 | $94 |
| Boehringer Ingelheim | 5 | $94 |
| Jubilant Hollisterstier LLC | 2 | $89 |
| Biogen | 1 | $84 |
| Incyte Corporation | 4 | $78 |
| Grifols USA, LLC | 4 | $77 |
| Organon | 5 | $65 |
| Johnson & Johnson | 2 | $57 |
| Aimmune Therapeutics, Inc. | 2 | $48 |
| Pharming Healthcare, Inc. | 1 | $16 |
| LEO Pharma Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Merck | 1 | $14 |
| Blueprint Medicines Corporation | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$7,453
- FASENRA$6,733
- NUCALA$3,250
- XOLAIR$2,543
- ArmonAir Digihaler$1,680
- ProAir Digihaler$1,680
- AirDuo RespiClick$1,680
- Xhance$800
- MINIMED 780G$411
- TEZSPIRE$244
- NEFFY$125
How this compares
$51,610 in reported general payments places this provider in the 90th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 61 | $250,145 |
| XolairOmalizumab | 57 | $177,960 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 116 | $95,587 |
| Dupixent PenDupilumab | 15 | $67,834 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $39,845 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $23,198 |
| Epinephrine | 95 | $18,655 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $14,029 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $11,692 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 30 | $7,347 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,628 |
| RyaltrisOlopatadine Hcl/Mometasone | 12 | $5,299 |
| Azelastine Hcl | 183 | $5,135 |
| DuleraMometasone/Formoterol | 13 | $5,032 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 164 | $4,550 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $173 | $177,96057 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $17,968 | $101,215130 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $199 | $39,84511 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,343 | $34,89068 claims |
| MerckDulera | $14 | $5,03213 claims |
| PfizerPaxlovid | $102 | $1,42912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in San Antonio
- Joseph DiazSan Antonio$1.1M
- Lukena KarkhanisSan Antonio$377K
- Araceli ElizaldeSan Antonio$51K
- Mark StahlSan Antonio$51K
- Robert RamirezSan Antonio$32K
- John DiceSan Antonio$19K
- Richard WassermanDallas$452K
- Matthew FeldmanDallas$410K
- Paul VigoAustin$304K
- Neha ReshamwalaAustin$303K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.